Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Sep 27, 2013; 5(9): 496-504
Published online Sep 27, 2013. doi: 10.4254/wjh.v5.i9.496
Published online Sep 27, 2013. doi: 10.4254/wjh.v5.i9.496
Ref. | Design/treatment | Duration (wk) | n | SVR | P value |
Nguyen et al[44] | Retrospective | 24 | 23 | 39% | 0.044 |
PEG-IFN 2a/2b + WB-RBV | 48 | 12 | 75% | ||
Lam et al[45] | Randomized (1:1) | 24 | 27 | 70% | 0.450 |
PEG-IFN 2a + WB-RBV | 48 | 33 | 79% | ||
Thu-Thuy et al[47] | Randomized (1:2) | 24 | 35 | 60% | 0.240 |
PEG-IFN 2a + WB-RBV | 48 | 70 | 71% | ||
Tangkijvanich et al[48] | Prospective | 24 if RVR achieved | 25 | 88% | NR |
PEG-IFN 2a + WB-RBV | 48 if no RVR | 9 | 44% |
- Citation: Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol 2013; 5(9): 496-504
- URL: https://www.wjgnet.com/1948-5182/full/v5/i9/496.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i9.496